Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2024 | Story Leonie Bolleurs | Photo SUPPLIED
Tebogo Motsei
Tebogo Motsei, a PhD student in Physics at the UFS, has been awarded the prestigious CV Raman International Fellowship for African Researchers.

Imagine a supercapacitor/battery made right here in South Africa that could change the way we store energy for the better. A product that can store energy in real time, thus solving energy problems as they happen, which makes a huge difference especially during power outages. A product that is not just good for the environment – transitioning away from lithium-ion batteries – but that can also create jobs and boost the local economy.

What we are talking about is a type of technology known as a sodium-ion supercapacitor/battery, which is the focus of Tebogo Motsei’s research. This technology serves as a power source for lighting, power plants, cars, and phones. Motsei, a PhD student in the Department of Physics on the Qwaqwa Campus of the University of the Free State (UFS), explains that – unlike lithium batteries, which have undergone extensive research and are expensive to produce – they are conducting experimental work and characterisations to determine if sodium-ion supercapacitor/batteries can perform as well or even better, using more affordable and eco-friendly materials.

“Our results, inspired by the urgent need for improved energy storage solutions in South Africa amid its energy challenges, have been very promising. We have successfully developed a sodium-ion supercapacitor/battery that stores as much energy as a lithium-ion battery. Moreover, it was crafted from recycled materials, making it a more cost-effective and environmentally friendly option,” states Motsei, adding that their battery is unique, as no one else in the world has created anything quite like it, despite numerous attempts.

She is also pleased with this supercapacitor/battery’s ability to repair itself. Motsei explains, “Imagine if your toy could fix itself whenever it got broken – that's kind of what our sodium-ion supercapacitor/battery does!”

Motsei is part of a group of scientists in the Department of Physics at the UFS who are working on this research and who have published a scientific article on their work, titled Composite super-capacitor/Na-ion battery with self-healing Fe–Cr alloy electrodes. 

“We're proud of what we have accomplished,” she remarks.

Fellowship: a dream come true

Being part of this impactful research contributed to Motsei receiving the prestigious CV Raman International Fellowship for African Researchers (2023). The fellowship is for African researchers engaged in research at an African institution, providing opportunities for research collaboration in India. Motsei will be the only candidate from South Africa.

This award is merit-based. Motsei attributes her selection to factors such as her strong academic record, research accomplishments, and innovative approach to solving complex problems. She also believes her experience in research, collaboration, and publication reflects her potential to make meaningful contributions to the field during the fellowship period. 

Another key factor contributing to her selection for this fellowship is her skill in fabricating actual devices/prototypes. “The hands-on nature of this research, allowing me to create devices from scratch, has always been my passion. Making my first device – the ‘Magnetron Sputtering Unit’ – during my master’s studies, was a turning point. It made me realise that I had made the best decision ever by choosing this research field. I'm truly passionate about my work,” says Motsei. 

For her PhD studies, she is supervised by Prof Richard Ocaya, Associate Professor in the Department of Physics, and co-supervised by Dr Kamohelo Tshabalala, Senior Lecturer in the Department of Physics. Prof Ocaya, proud of Motsei’s achievements, believes that this fellowship not only serves as a great motivation for students – especially on the Qwaqwa Campus – but also highlights the global relevance of the UFS, particularly the Department of Physics.

Motsei says receiving this fellowship is a dream come true and a profound, life-changing moment for her. “I feel deeply honoured to be concluding this programme at the CSIR-Electrochemical Research Institute, the host institution in India, under the guidance of Prof Arul Manuel Stephan, whose invaluable assistance has been instrumental in my preparations.” Motsei also expressed her gratitude towards everyone who has supported her during this process, including Sudhir Kumar from the Indian Embassy in Pretoria.

“I am excited about how I can use this opportunity to make a difference. Whether it’s tackling significant global energy issues or finding new ways to solve everyday problems, I know this fellowship will give me the tools and support needed to make a real impact. Overall, I see this fellowship as a stepping stone to exciting new opportunities and adventures in the world of research,” she comments.

Making a meaningful impact

Motsei will be leaving for India on 23 February for a period of six months. She is excited about this new chapter in her research journey. “This fellowship will enhance my abilities as a scientist and leader in physics, providing me with essential skills, connections, and experience to make a meaningful impact in science and energy. I'm genuinely happy about this opportunity, which I thank God for.”

  • Sir Chandrasekhara Venkata Raman, after whom the fellowship is named, was a renowned Indian physicist who made great contributions to physics, winning many prizes and awards, including the 1930 Nobel Prize in Physics. He was known for his work in the field of light scattering and was the first Asian and non-European to receive a Nobel prize in any branch of science. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept